Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051508 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8063417 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15145661 | 0.88 | PPID (0.60) | ROCK2ROCK1SMN1; SMN2PPIDNPC1 | |
| SCHEMBL7141146 | 0.86 | ROCK2 (0.59) | ROCK2ROCK1SMN1; SMN2HIF1AMMP3 | |
| SCHEMBL8062348 | 0.85 | ROCK2 (0.41) | ROCK2ROCK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18595025 | 0.84 | ROCK2 (0.55) | ROCK2ROCK1SMN1; SMN2HIF1ALCK | |
| SCHEMBL18595010 | 0.83 | ROCK2 (0.59) | ROCK2ROCK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7139835 | 0.83 | ROCK2 (0.39) | ROCK2ROCK1 | |
| SCHEMBL7139827 | 0.83 | ROCK2 (0.39) | ROCK2ROCK1 | |
| SCHEMBL8067759 | 0.82 | ROCK2 (0.43) | ROCK2ROCK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | ROCK2 180/4885ROCK1 62/4885SMN1; SMN2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.